Combining Memantine and Cholinesterase inhibitors in Lewy body dementia treatment trial (COBALT)
Theme Group:
Clinical Trials and Therapeutics
About the project:
Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are two neurodegenerative cause of dementia, in which patients are generally treated with Cholinesterase inhibitors. This is an NIHR Health Technology Assessment funded international multi-centre trial examining the efficacy of combined treatment with Memantine. The Southampton site for this trial is the Memory Assessment and Research Centre, Moorgreen Hospital.
Key iDeAC expertise:
Dr Jay Amin
Clinical Trials
Related projects:
Use of antisense oligonucleotide in Progressive supranuclear palsy
Treating impulsivity in people with progressive supranuclear palsy
Using electronic patient records to examine patient outcomes in Dementia with Lewy bodies
Combining Memantine and Cholinesterase inhibitors in Lewy body dementia treatment trial (COBALT)
Phase 1 trial of bepranemab in progressive supranuclear palsy
Permeability of the blood-brain barrier in Alzheimer’s disease (PEBBAL) measured using dynamic contrast-enhanced MRI: a pilot study
Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy aging and neurodegenerative disease (BIO-AGE)